Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2006-02-28
2006-02-28
Chan, Christina (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C530S350000
Reexamination Certificate
active
07005498
ABSTRACT:
A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.
REFERENCES:
patent: 5736142 (1998-04-01), Sette et al.
patent: 2002/0090379 (2002-07-01), Mouritsen et al.
patent: 378881 (1990-07-01), None
patent: 0427347 (1991-05-01), None
patent: WO9505849 (1995-03-01), None
patent: WO9507707 (1995-03-01), None
patent: WO 86/07383 (1996-12-01), None
patent: WO 96/40789 (1996-12-01), None
patent: WO9741227 (1997-11-01), None
patent: WO9823635 (1998-06-01), None
patent: WO9831398 (1998-07-01), None
patent: WO 99/56919 (1998-12-01), None
patent: WO 99/10375 (1999-03-01), None
patent: WO 99/40188 (1999-08-01), None
Fendly et al. Vaccine Research vol. 2, No. 3, 1991, pp. 129-139.
A13Geneseq13101002 Accession No. AAR06310, Dec. 1990.
A13Geneseq13101002 Accession No. AAW11505, Sep. 1997.
A13Geneseq13101002 Accession No. AAR11896, Jul. 1991.
Dalum et al. J. Immunol. vol. 157, 1996, pp. 4796-4804.
Zavala et al. J. Exp. Med. 1983, vol. 157, pp. 1947-1957.
Dalum, Iben et al.; “Therapeutic . . ” Nature Biotech. vol. 17, Jul. 1999, p. 656-659.
Mackey, Matthew et al.; “Cutting Edge . . ” Journal of Immunology pp. 2094-2096, 1998.
Ridge, John P. et al.; “A conditined . . ” Nature vol. 393, Jun. 4, 1998, pp. 474-478.
Gemel, Joanna et al.; “structure and . . ” Genomics 35, 253-257 (1996).
Dalum, Iben et al.; “Breaking of B Cell . . ” Amer. Assoc. of Immunology pp. 4796-4804.
Tjoa, Benjamin et al.; “Presentation od . . ” The Prostate 25:266-271 (1996).
Chicz, Roman M. et al.; “Specificity and . . ” J. Exp. Med. vol. 178, Jul.-1993, 27-47.
Candia, Albert F. et al.; “Mox-1 and . . ” Development 116, 1123-1136 (1992).
O'Sullivan, Deirdre et al.; “On the Interaction . . ” J. of Immunology vol. 147, 2663-2669, No. 3, Oct. 15, 1991.
Furukawa, Keiko S. et al.; “A Unique . . ” J. Exp. Med. vol. 169, pp. 585-590 Feb. 1989.
Jacoby, David R. et al.; “Immunologic . . ” Advances in Immunology, vol. 35, pp. 157-208, 1984.
Hopp, Thomas P. et al.; “A Computer . . ” Molecular Immunology vol. 20, No. 4 pp. 483-489 (1983).
Dalum, Iben et al., “Induction of cross-reactive antibodies against a self protein by immunizing with a modified self protein containing a foreign T helper Epitope,” Molecular Immunology, 1997, vol. 34, No. 16-17, pp. 1113-1120.
Janeway, Immuno Biology 3rdEdition, Garland Publishing Inc, 1997, page 21.
Leach, Dana, “Vaccination with Modified HRR-2 Molecules . . . , ” 11thInternational Congress of Immunology, Theme 3 pg. 74.
Steinaa, Lucilla, “Cognate T-Cell help breaks Cytotoxic T Lymphocyte (CTL) Tolerance Against Self-Antigens,” 11thInternational Congress of Immunology, Theme 3, pg. 73.
Widmann, C., et al., “T helper epitopes enhance the cytotoxic,” Journal of Immunological Methods, 155 (1992), pp. 95-99.
Alexander, J. et al., “The optimization of helper t lymphocyte13,”Immunologic Research 1998: 18/2. pp. 79-92.
Stoute, J. et al., “A preliminary evaluation of a recombinant13,” The New England Journal of Medicine, 1997, vol. 336 (2), pp. 86-91.
Hanke, T et al., “DNA multi-CTL epitope vaccine13, ” Vaccine, 1998, vol. 16, No. 4, pp. 426-435.
Gilbert, S. et al., A protein particle vaccine containing multiple13, Nature Biotechnology, Nov. 1997, vol. 15, pp. 1280.
Yang, Kiao-Dong et al., “Eradication of . . . ”Cancer Research 59 1236-1243, Apr. 15, 1999.
Kass, Erik et al., “Induction of . . ” Cancer Research 59, 676-679 Jun. 1999.
Vonderheide, Robert H. et al., The Tolerance . . . Immunity Vol. 10, 673-679 Jun. 1999.
Kikuchi, Megumi et al., “Identification of a . . ”Int. J. Cancer: 81: 459-466 1999.
Marchand, Marie et al.; “Tumor Regressions . . ”Int. J. Cancer: 80: 219-230 1999.
Sandmaier, Brenda et al., “Evidence of . . ” Journal of Immunotherapy 22(1): 54-66.
Graft tolerance., “Nature Medicine vol. 5, Jun. 1999.
Wang, Rong-Fu et al.; “Cloning Genes . .” Science vol. 284, May 21, 1999.
Sanda, Martin G. et al., “Recombinant Vaccina . . ” Urology 53 (2) 1999.
Kirkin, Alexei F. et al., “Melanoma-associated . . ” Armis 106: 663-679, 1993.
Klote, Theo et al., “Selective Expression
Divigi, Chaitanya R. et al., “Phase I/II . . . ”Clinical Cancer Research vol. 4, 2729-2739 Nov. 1998.
Ossendorf, Ferry et al.; “Specific T Helper . . . ”J. Exp. Med. vol. 187, No. 5, 3-2-1998 pp. 693-702.
Jager, Elke wt al., “Simultaneous Humoral., ”J. Exp. Med. vol. 187, No. 2, Jan. 199, 1998, pp. 265-270.
Southwood, Scott et al., “Several Common . . . ”Journal of Immunology pp. 3363-3373.
Schoenberger, Stephen et al., “T-cell help,” Nature vol. 393, Jun. 4, 1998.
Bennett, Sally R.M. et al.;“Help for..”Nature vol. 393, Jun. 4, 1998.
Lanzavecchia, Antonio, “License to Kill ” Nature vol. 393, Jun. 4, 1998.
Wagner, Stephen N. et al, “Expression and function . . . ”Int. J. Cancer: 71. 1049-1055 1997.
Jarvis, Gary A. et al, “Expression and function . . . ”Int. J. Cancer: 71 1049-1055 1997.
Knox, Susan J., et al., “ Ye exium-90-labeled . . ”Clinical Cancer Research vol. 2, pp. 457-470 Mrch 1996.
Ghosh, Ananta K, et al; “Molecular Cloning . . . ”Cell Growth vol. 7, 1425-1434 Oct. 1996.
Rock, Kenneth L. et al.; “Analysis of the . . . ”Ame. Assoc. Immunology 3721-3726.
Murphy, G.P. et al., “Measurement of . . . ”the Prostate 25: 266-271 (1996).
Abrams, Scott Y. et al.; “Mutant ras . . . ”Seminars in Oncology vol. 23, No. 1 (February) 1996: pp. 118-134.
Wright, George L. et al., “Upregulation of . . . ”Urology 48 (2) 1996.
Rock, Edwin P. et al., “Immunology of a . . . ”Vaccine 1996 vol. 14, No. 16.
Murphy, gerald et al., “Comparison of . . . ”Anticancer Research 15: 1473-1480 (1995).
Ohnishi, Y et al., “Prolonged survival . . . ”British J. of Cancer (1995) 71, 969-973.
Wiener, Louis M., et al.; “Phase I Trial., ”Cancer Research 55, 4586-4593, Oct. 15, 1995.
Macarthur, Craig A. et al., “FGRF-8 Isoforms . . ”Cell Growth vol. 6, 817-825 Jul. 1995.
Salomon, David S. et al., “Epidermal growth. . ” Critical reviews in Oncology/Hematology 19 (1995) 183-232.
Crossley, Phillip H. et al., “The mouse Fgf8 . . ”Development 121, 439-451 (1995).
Rammensee, Hans-Georg et al., “MMC ligands . . ” Immunogentics (1995) 41: 178-226.
Zhu, Zhenping et al., “Engineering high . . ”Int. J. Cancer: 62, 319-324 (1995).
Tjoa, Benhamin et al., “In Vittro . . ”The Prostate 27: 63-69 (1995).
“OLFEL, Thomas et al., ”A p16ink4a . . Science vol. 269, Sep. 1, 1995.
Lewis, Jonathon J. et al.; “Definition of J. ” Cancer Biology, vol. 6, 1995: pp. 321-327.
Lupu, Ruth et al., “Interaction between . .
Dalum Iben
Gautam Anand
Hanning Jesper
Karlsson Gunilla
Leach Dana
Birch & Stewart Kolasch & Birch, LLP
Chan Christina
DiBrino Marianne
Pharmexa A/s
LandOfFree
Methods for therapeutic vaccination does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for therapeutic vaccination, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for therapeutic vaccination will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3671413